Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The HCG Institute is mentioned for reference only and does not constitute an endorsement or recommendation
Data availability The datasets generated and analysed during the current study are not publicly available due to ethical consideration, but are available from the corresponding author on reasonable request
Tirzepatide: SURMOUNT trial results The SURMOUNT program represents the largest clinical trial dataset for tirzepatide weight loss
However, FAERS has well-known limitations: Reports are spontaneous and incomplete Reporting stimulated by media attention and warnings No denominator (unknown number of exposed users) Thyroid cancer not subtype-adjudicated Confirmation bias (clinicians primed to connect drug and outcome) FAERS can answer: "Is this being reported more?" It cannot answer: "Does this drug cause thyroid cancer?" Appropriate Use of FAERS: FAERS findings are hypothesis-generating signals requiring controlled observational worknot evidence of causality
US$ 23.58
US$ 21.89
US$ 21.12
US$ 22.88
US$ 20.38
US$ 20.31
US$ 27.31
